Compare Abbott Laboratories (ABT) vs KE Holdings Inc (BEKE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs KE Holdings Inc — how do they compare? Abbott Laboratories trades at $95.25 (market cap $166.94B), while KE Holdings Inc trades at $15.34 (market cap $16.40B). The key difference: Abbott Laboratories is far larger — about 10.2× KE Holdings Inc's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | BEKE | |
|---|---|---|
Market Cap | $166.94B | $16.40B |
Sector | Health | Technology |
52-Week High | $136.62 | $20.36 |
52-Week Low | $82.57 | $14.26 |
Enterprise Value | $193.69B | $12.17B |
Dividend Yield | 2.63% | 1.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
BEKE trades at $15.02, down 0.46% with a bearish technical signal. The company reported strong Q1 2026 earnings beating expectations with EPS of $0.20 versus $0.14 expected, driven by improved profitability despite lower revenue. Analyst sentiment remains overwhelmingly positive with 91.7% buy ratings. Recent news highlights potential trend reversal opportunities after a 14.1% decline over four weeks.
The outlook suggests potential upside with improving operational efficiency and cost controls offsetting market softness. Key risks include China's property market volatility and competitive pressures. With strong institutional support and positive earnings momentum, BEKE presents a compelling growth story despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About KE Holdings Inc
KE Holdings (Beike) is China’s leading platform for housing transactions and services. It operates the Lianjia brand and uses data-driven technology to facilitate home sales, rentals, and home renovation services.
Read more on BEKE →
